Why venture philanthropy works
Venture philanthropy applies the principles of venture capital – a type of financing in which investors fund startup companies with potential for rapid value creation – to invest with a charitable mission. The MIF applies the principles of venture capital to the development of new myeloma treatments.
Venture philanthropy funds from the MIF direct resources toward therapies and technologies with the potential to transform patient care by investing in the companies that are developing them early on. Importantly, the MIF is funded exclusively through charitable donations, and 100% of all returns from MIF investments are reinvested into the fund to drive further development of novel therapies.
Because of the MIF’s mission-driven focus, the fund also offers a source of stability. The drug development process involves long timelines and a high degree of scientific risk, and many investors move in and out of the biotech sector depending on their risk tolerance.
The MIF, on the other hand, does not prioritize short-term financial returns. Our investments are mission driven – guided by our singular goal to accelerate the development of novel therapies which could lead to cures for each and every multiple myeloma patient.